COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 725: Articles 7241-7250  | Next

Predictions of immunogenicity reveal potent SARS-CoV-2 CD8+ T-cell epitopes
Gfeller, D., Schmidt, J., Croce, G., Guillaume, P., Bobisse, S., Genolet, R., Queiroz, L., Cesbron, J., Racle, J., Harari, A.
10.1101/2022.05.23.492800 — Posted: 2022-05-23
Using a reverse genetics system to generate recombinant SARS-CoV-2 expressing robust levels of reporter genes
Ye, C., Martinez-Sobrido, L.
10.1101/2022.05.21.492922 — Posted: 2022-05-23
Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course
Muri, J., Cecchinato, V., Cavalli, A., Shanbhag, A. A., Matkovic, M., Biggiogero, M., Maida, P. A., Toscano, C., Ghovehoud, E., Danelon-Sargenti, G., Gong, T., Piffaretti, P., Bianchini, F., Crivelli, V., Podesvova, L., Pedotti, M., Jarrossay, D., Sgrignani, J., Thelen, S., Uhr, M., Bernasconi, E., Rauch, A., Manzo, A., Ciurea, A., Rocchi, M. B. L., Varani, L., Moser, B., Thelen, M., Garzoni, C., Franzetti-Pellanda, A., Uguccioni, M., Robbiani, D. F.
10.1101/2022.05.23.493121 — Posted: 2022-05-23
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
Le Nouen, C., Nelson, C. E., Liu, X., Park, H.-S., Matsuoka, Y., Luongo, C., Santos, C., Yang, L., Herbert, R., Castens, A., Moore, I. N., Wilder-Kofie, T., Moore, R., Walker, A., Zhang, P., Lusso, P., Johnson, R. F., Garza, N. L., Via, L. E., Munir, S., Barber, D., Buchholz, U. J.
10.1101/2022.05.21.492923 — Posted: 2022-05-23
The SARS-CoV-2 spike protein binds and modulates estrogen receptors
Solis, O., Beccari, A. R., Iaconis, D., Talarico, C., Ruiz-Bedoya, C. A., Nwachukwu, J. C., Cimini, A., Castelli, V., Bertini, R., Montopoli, M., Cocetta, V., Borocci, S., Prandi, I. G., Flavahan, K., Bahr, M., Napiorkowski, A., Chillemi, G., Ooka, M., Yang, X., Zhang, S., Xia, M., Zheng, W., Bonaventura, J., Pomper, M. G., Hooper, J. E., Morales, M., Rosenberg, A. Z., Nettles, K. W., Jain, S. K., Allegretti, M., Michaelides, M.
10.1101/2022.05.21.492920 — Posted: 2022-05-23
Reduced Neutralization of SARS-CoV-2 Omicron Variant in Sera from SARS-CoV-1 Survivors after 3-dose of Vaccination
Zhao, X., Chen, D., Hao, X., Qiu, Y., Du, J., Zhang, Y., Xiao, F., Li, X., Song, Y., Song, R., Wang, X., Jin, R.
10.1101/2022.05.21.492903 — Posted: 2022-05-23
Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines
Desikan, R., Linderman, S. L., Davis, C. W., Zarnitsyna, V. I., Ahmed, H. R., Antia, R.
10.1101/2022.05.21.492928 — Posted: 2022-05-23
Variant-specific symptoms of COVID-19 among 1,542,510 people in England
Whitaker, M., Elliott, J., Bodinier, B., Barclay, W. S., Ward, H., Cooke, G., Donnelly, C. A., Chadeau-Hyam, M., Elliott, P.
10.1101/2022.05.21.22275368 — Posted: 2022-05-23
Patient satisfaction with telemedicine in the Philippines during the COVID-19 pandemic
Noceda, A. V. G., Acierto, L. M. M., Bertiz, M. C. C., Dionisio, D. E. H., Laurito, C. B. L., Sanchez, G. A. T., Amit, A. M. L.
10.1101/2022.05.21.22274939 — Posted: 2022-05-23
Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years in Germany (CoVacU5): An Investigator-initiated Retrospective Cohort Study
Toepfner, N., von Meissner, W. C. G., Strumann, C., Drinka, D., Stuppe, D., Jorczyk, M., Moor, J., Pueschel, J., Liss, M., von Poblotzki, E., Berner, R., Moor, M. B., Chao, C.-M.
10.1101/2022.05.17.22275005 — Posted: 2022-05-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).